January 29, 2023


Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) stock price hit a fresh 52-week high during Monday trading after Piper Sandler raised her price target on the stock to $47.00 from $40.00 . Piper Sandler is currently overweight the stock. Supernus Pharmaceuticals traded as high as $41.25 and last at $40.55 with volume of 28,008 shares traded. The stock had previously closed at $40.31.

Separately, StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong buy” rating in a research report on Friday, January 13th.

Insider activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 25,446 shares of the company’s shares in a transaction on Tuesday, Jan. 17. The stock sold at an average price of $40.03 for a total value of $1,018,603.38. Following the sale, the Chief Executive Officer now owns 791,173 shares of the Company, valued at approximately $31,670,655.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, available at this link. In related news, CEO Jack A. Khattar sold 25,446 shares of the company’s shares in a transaction on Tuesday, Jan. 17. The stock sold at an average price of $40.03 for a total value of $1,018,603.38. Following the sale, the Chief Executive Officer now owns 791,173 shares of the Company, valued at approximately $31,670,655.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, available at this link. Also, CEO Jack A. Khattar sold 1,115 shares of the company’s stock in a transaction on Tuesday, November 15. The stock sold at an average price of $35.00 for a total value of $39,025.00. Following the sale, the Chief Executive Officer now owns 780,742 shares of the Company, valued at approximately $27,325,970. The disclosure for this sale can be found here. Over the past 90 days, insiders have sold 69,340 shares of the company’s shares, valued at $2,629,303. 8.70% of the shares are currently owned by company insiders.

Institutional investors rely on Supernus Pharmaceuticals

Several major investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its stake in Supernus Pharmaceuticals by 535.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 61,259 shares of the specialty pharmaceutical company valued at $2,185,000 after purchasing an additional 51,613 shares during the period. The Maryland State Retirement & Pension System acquired a new position in Supernus Pharmaceuticals stock valued at about $789,000 during the fourth quarter. Exchange Traded Concepts LLC increased its position in Supernus Pharmaceuticals by 2.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 19,938 shares of the specialty pharmaceutical company, valued at $711,000, after purchasing an additional 540 shares last quarter. Assenagon Asset Management SA increased its position in shares of Supernus Pharmaceuticals by 298.0% in the fourth quarter. Assenagon Asset Management SA now owns 168,010 shares of the specialty pharmaceutical company, valued at $5,993,000, after acquiring an additional 125,795 shares last quarter. Finally, the Alaska Department of Treasury increased its position in shares of Supernus Pharmaceuticals by 1.5% in the fourth quarter. The Alaska Department of Treasury now owns 37,642 shares of the specialty pharmaceutical company, valued at $1,342,000, after purchasing an additional 572 shares last quarter. Hedge funds and other institutional investors own 99.82% of the company’s shares.

Supernus Pharmaceuticals stock performance

The company has a 50-day moving average price of $36.90 and a 200-day moving average price of $34.41. The company has a market cap of $2.23 billion, a price-to-earnings ratio of 64.34 and a beta of 0.94.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last released its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported earnings per share (EPS) of $0.03 for the quarter, beating the consensus estimate of $0.32 ($0.29). The company had revenue of $177.35 million for the quarter, compared to analyst estimates of $173.22 million. Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. On average, research analysts expect Supernus Pharmaceuticals, Inc. to report earnings per share of 1.63 for the current fiscal year.

About Supernus Pharmaceuticals

(get rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) disorders in the United States. Its commercial products are Trokendi XR, an extended-release topiramate product indicated for the treatment of epilepsy and the prophylaxis of migraine headaches; and Oxtellar XR, an extended-release oxcarbazepine for monotherapy in partial-onset epileptic seizures in adults and children 6 to 17 years of age.

Featured Stories



Receive News & Reviews for Supernus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *